Numab Therapeutics AG

The week before the annual J.P. Morgan Healthcare Conference always brings a flurry of new venture capital financings and the tradition continued in 2025, including Aviceda Therapeutics with a $207.5m

Johnson & Johnson has a proven track record in immunology with the development of mega-brands like Remicade (infliximab), Stelara (ustekinumab), Tremfya (guselkumab) and Simponi (golimumab), acros

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Otsuka Pays $10m Up Front For Ion

PureTech Health plc, after the multibillion-dollar success of its last neuropsychiatry venture Karuna Therapeutics Inc., launched Seaport Therapeutics in April with $100m in series A funding and on 21